Journal of Oncology / 2020 / Article / Tab 8

Research Article

Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 8

Overall and progression-free survival according to second-line chemotherapy regimen in the overall population and the group of patients diagnosed during study enrolment.

Overall populationDiagnosed during enrolment
Median95% CI valueMedian95% CI value

OS (months)
Nab-paclitaxel-gemcitabine8.36.0–10.70.7857.56.1–8.90.751
FOLFIRINOX/CAPOXIRI13.45.8–21.011.84.3–19.3
FOLFOX/CAPOX7.66.5–8.87.61.8–13.4
Other regimens8.95.2–12.66.52.7–10.2

PFS (months)
Nab-paclitaxel-gemcitabine4.53.7–5.30.1944.53.6–5.40.584
FOLFIRINOX/CAPOXIRI8.06.4–9.66.90.5–13.3
Gemcitabine4.92.8–7.04.41.6–7.2
Other regimens6.34.4–8.36.12.2–9.9

CAPOXIRI, oxaliplatin/irinotecan/capecitabine; 95% CI, 95% confidence intervals; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil; OS, overall survival; PFS; progression-free survival.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.